| 영문 | renal cell carcinoma | 한글 | 콩팥세포암종 |
|---|---|---|---|
| 설명 | 콩팥에 생긴 원시콩팥조직에서 발생한 암. 주로 원시세뇨관조직에서 발생한다. 대표적인 세포조직형은 염색시 세포질이 맑게 비어보이는 맑은세포암종이다. 치료는 수술과 항암화학요법이며 아주 드물지만 저절로 낫는 경우도 있는 것으로 보고되어 있다. |
||
| 영문 | squamous cell carcinoma | 한글 | 편평세포암종 |
|---|---|---|---|
| 설명 | 편평세포 기원의 암으로서, 편평세포가 있는 어떤 곳에서든 발생가능함. 따라서 식도암, 피부암, 폐암, 자궁암 등이 여기에 해당된다. 특히 피부암은 많은 자외선조사에 의해 생기는 광선각화증에서 발생가능하다. 병리조직학적 특성으로서 각질을 생성한다. |
||
| 영문 | thyroid carcinoma | 한글 | 갑상샘암종 |
|---|---|---|---|
| 설명 | 갑상샘에 생긴 상피세포로 이루어진 악성종양물. 병리조직학적인 형태에 따라 유두상, 소포상, 역형암종 및 수질암종, 림프종 등으로 나눌 수 있다. 다양한 원인이 있으나, 일부에서는 방사선폭로에 의해 발생한다. 치료는 수술, 방사성 옥소, T4 억제요법 등이 사용된다. |
||
| 영문 | bronchogenic carcinoma | 한글 | 기관지원성 암종 |
|---|---|---|---|
| 설명 | 폐의 기관지 세포에서 기원하는 종양. 폐암의 종류에서 가장 흔한 형태(90%이상)이다. 현미경적 소견에 따라 샘암종, 큰세포암종, 소세포(작은세포) 암종의 4가지로 나눈다. 이중에서 편평세포암종이 가장 흔한 형태이다. 임상적으로는 비소세포폐암(non-small cell lung cancer)와 소세포폐암(small cell lung cancer)로 구분을 하는데, 비소세포폐암의 경우 종양세포의 성장이 느리고 수술적 제거가 치료의 기본이 되고 예후도 좋은 반면, 소세포폐암의 경우에는 암세포의 성장이 매우 빠르고 치료도 방사선치료를 기본으로 하며 예후도 비소세포폐암에 비해서 좋지가 못하다. |
||
| 영문 | embryonal carcinoma | 한글 | 배아암종 |
|---|---|---|---|
| 설명 | 생식세포에서 생기는 암종의 하나로 대부분 고환에서 발생한다. 드물게는 종격동에서도 발생한다. 40~50대의 남성에게 많으나, 이보다 낮은 연령층에서도 나타난다. 육안적으로는 회백색의 분엽을 보이는 덩어리를 형성하며, 고환 악성 종양 중 예후가 좋은 편이다. 치료의 원칙은 가급적 신속하게 원발소를 절제하고 예상되는 전이병터에 대하여 방사선 조사요법을 행해야 한다. 태생암종 방사선요법에 대하여 매우 감수성이 높기 때문에 병기가 초기이면 90% 이상의 치료가 기대된다. 그리고 화학요법제에 의해 그 치료성과가 상승하고 있다. |
||
| ACC | accommodation; acetyl coenzyme A carboxylase; acinic cell carcinoma; acute care center; adenoid cyst... |
|---|---|
| EC | effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme... |
| SCC | self-care center; sequential combination chemotherapy; services for crippled children; short-course ... |
| MEN | Multiple Endocrine Neoplasia ; AD Trait 1. MEN Type I(= Wermer Syndro... |
| MC | mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med... |
| ICA | Islet Cell-Cytoplasmic Antibodies |
|---|---|
| ICA | Islet cell |
| ICA | Islet cell antibodies |
| ICAs | Islet cell antibodies |
| ICA | Islet cell antibody |
| carcinoma, islet cell | A carcinoma of the islets of langerhans. (12 Dec 1998) |
|---|
| adenoma, islet cell | A benign tumour of the islets of langerhans that may occur anywhere throughout the pancreas. Such tumours may result in hyperinsulinism or zollinger-ellison syndrome. (12 Dec 1998) |
|---|---|
| pancreatic isleT-cell tumours | <radiology> Insulinoma (beta-cell), usually solitary, 85% benign, gastrinoma, small, slow-growing, multiple, 60% malignant, Zollinger-Ellison syndrome: mult. Intractable ulcers, VIPoma, vasoactive intestinal peptide (VIP), WDHA syndrome: watery diarrhoea, hypokalaemia, achlorhydria, Verner-Morrison syndrome, glucagonoma, hyperglycaemia, migratory necrolytic erythema APUDomas, associated with MEN-1 (12 Dec 1998) |
| islet cell | <pathology> Cells of the Islets of Langerhans within the pancreas. See: A cells, B-cells, D cells. (18 Nov 1997) |
| islet cell adenoma | <tumour> A benign neoplasm of the pancreas composed of tissue similar in structure to that of the islets of Langerhans; it may contain functioning beta cells, and may cause hypoglycaemia. See: insulinoma. Synonym: nesidioblastoma. (05 Mar 2000) |
| islet cell antibodies | In first-degree relatives of probands with insulin-dependent diabetes mellitus the presence of high titre ICA of the IgG cytoplasmic variety (IgG -ICA) and ICA of the complement-fixing subgroup (CF-ICA) confer a relative risk of 75 for development of insulin-dependent diabetes mellitus. The presence of ICA combined with a decrease in the first-phase of insulin secretion ( less than 25 micro U/mL) is predictive with a 95% likelihood of the development of insulin-dependent diabetes mellitus within 12 months. Reproducible results among laboratories are possible with careful attention to selection of the human pancreas as substrate as well as to the use of dilutions to generate standard curves and to the conversion of results to units. The prozone phenomena described elsewhere are not common in our experience. Fifty percent of relatives with a single positive ICA test will develop insulin-dependent diabetes mellitus within 10 years, and 60-80% of relatives with both ICA and insulin autoantibodies (IAA) will develop insulin-dependent diabetes mellitus within 10 years. The predictive value for health of negative results for ICA and IAA is almost 99%. Strong, persistently positive ICA (i.e., 40 JDF U or greater), especially if accompanied by markedly decreased insulin secretion, are the best predictors of subsequent development of insulin-dependent diabetes mellitus. The 64 kD beta-cell autoantigen long thought to be an important target for ICA is not yet available from expression cloning despite efforts by several groups.13 ICA positivity correlates with rapid loss of C-peptide secretory capacity in newly diagnosed ICA-positive insulin-dependent diabetes mellitus. The predictive values of ICA for development of insulin-dependent diabetes mellitus within 10 years in first-degree relatives of patients with insulin-dependent diabetes mellitus increase from 40% at low levels of ICA to 100% at high levels, whereas the sensitivity is 88% at low levels and 31% at high levels. In general, the risk of insulin-dependent diabetes mellitus in relatives of probands increases with titre of ICA, is greater in multiplex families, and is increased in those less than 10 years of age with positive ICA. Although the prevalence of ICA in Japanese with autoimmune thyroid disease resembles that in Caucasians, the incidence of insulin-dependent diabetes mellitus in the Japanese population is only 1/30 - 1/50 that in Caucasians. Prediabetics positive for ICA and IAA have increased suppressor-inducer (CD45R) and decreased helper-inducer (CDw29) peripheral blood lymphocytes. In two randomised, prospective, placebo-controlled studies of recent-onset insulin-dependent diabetes mellitus, cyclosporine immunosuppression increased the rate of non-insulin-requiring remissions as well as beta-cell function during drug treatment. Although 12 months of cyclosporine therapy decreases titres of ICA and insulin antibodies (IA) and increases glucagon-stimulated levels of serum C-peptide, the determination of ICA and IA and HLA-DR type are of no predictive value in selecting recent- onset insulin-dependent diabetes mellitus. Patients for cyclosporine immunointervention. Genetic control of autoimmunity in insulin-dependent diabetes mellitus is reviewed. EIA for autoantibodies to a 64 kD islet-cell protein is promising for prediction of insulin-dependent diabetes mellitus, but sensitivity and specificity are still suboptimal. See also: insulin antibodies. (05 Mar 2000) |
| islet cell antigen-related protein-tyrosine phosphatase | <enzyme> Receptor-like autoantigen found in insulin-dependent diabetes; genbank l76258 Registry number: EC 3.1.3.- Synonym: iar ptp (26 Jun 1999) |
| islet-cell-stimulating antibodies | <immunology> Autoantibodies to a putative beta-cell receptor; stimulate the release of insulin both in rodents and man; may be analogous to the thyroid stimulating antibodies that cause grave's hyperthyroidism Synonym: icsta (05 Dec 1998) |
| blood islet | An aggregation of splanchnic mesodermal cells on the embryonic yolk sac, with the potentiality of forming vascular endothelium and primitive blood cells. Synonym: blood islet. (05 Mar 2000) |
| islet | A small island. (05 Mar 2000) |
| islet amyloid peptide | <hormone, protein> Peptide of 37 amino acids that selectively inhibits insulin stimulated glucose uptake in muscle. Structurally related to calcitonin gene-related peptide. (15 Oct 1997) |
| islet neogenesis-associated protein | <chemical> Constituent of ilotropin; stimulates proliferation of pancreatic ductal cells in vitro; from hamsters and humans; amino acid sequence given in first source Synonym: ingap protein, ingap gene product (05 Dec 1998) |
| islet tissue | <anatomy> Groups of cells found within the pancreas: A cells and B-cells secrete insulin and glucagon. See: D cells. (18 Nov 1997) |
| acinic cell carcinoma | <tumour> An adenocarcinoma arising from secreting cells of a racemose gland, particularly the salivary glands. Synonym: acinar carcinoma, acinic cell carcinoma, acinose carcinoma, acinous carcinoma. (05 Mar 2000) |
| adenoid squamous cell carcinoma | <tumour> A malignant neoplasm consisting chiefly of glandular epithelium (adenocarcinoma), usually well differentiated, with foci of metaplasia to squamous (or epidermoid) neoplastic cells. Synonym: adenoid squamous cell carcinoma. (05 Mar 2000) |
| alveolar cell carcinoma | <tumour> A carcinoma, thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli; involvement may be uniformly diffuse and massive, or nodular, or lobular; microscopically, the neoplastic cells are cuboidal or columnar and form papillary structures; mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells; metastases in regional lymph nodes, and even in more distant sites, are known to occur, but are infrequent. Synonym: alveolar cell carcinoma, bronchiolar adenocarcinoma, bronchiolo-alveolar carcinoma, bronchioloalveolar adenocarcinoma. (05 Mar 2000) |
Synonyms : Carcinomas, Islet Cell, Islet Cell Carcinoma, Islet Cell Carcinomas
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|